Logo small
Acute myeloid leukemia

Prof. Agnieszka Wierzbowska: We are witnessing a major breakthrough

MedExpress Team

Published Feb. 13, 2024 08:00

Prof. Agnieszka Wierzbowska: We are witnessing a major breakthrough - Header image
Are we treating acute myeloid leukemia in Poland according to international guidelines? How do targeted therapies change the treatment outlook? Prof. Agnieszka Wierzbowska of the Department of Hematology at the Medical University of Lodz says.

What does new medicine offer today for patients with acute myeloid leukemia, but in slightly worse shape, older, with comorbidities, who are not eligible for chemotherapy or transplantation?

Over the past three years, treatment prospects have changed for this group of patients. Until now, it was thought that there was little we could do to help elderly patients who were not eligible for intensive treatment; we were trying to prolong overall survival and improve quality of life. One breakthrough was the introduction of hypomethylating drugs more than 10 years ago. Nevertheless, the most effective treatments still did not lead to satisfactory results. I am referring primarily to the relatively short overall survival time with a median of 7-8 months. A big step was the introduction of venetoclax in combination with azacitidine. This is a relatively universal treatment that has further extended median overall survival. I think we are now witnessing a major breakthrough, because for the treatment of elderly people inel...

Content locked

To gain access to the complete English section of the, kindly reach out to us at [email protected].

If you already have an account, please log in

Similar articles

Zrzut ekranu 2024-02-5 o 12.55.18
Feb. 8, 2024
April 19, 2022
Terapia AML

A breakthrough we still can't benefit from

Feb. 28, 2022
Feb. 9, 2022
July 24, 2024

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.